Calidi Biotherapeutics is exploring targeted immune activation through CLD-401 and its systemic oncolytic virotherapy platform.
Public source
Publisher name
Public post
What’s next for #CancerDrugDiscovery? In Morgan Kohler's new Drug Discovery Online article, #CalidiBiotherapeutics' CEO Eric Poma, Ph.D. shares his perspective on target…
Company
Calidi Biotherapeutics
Pioneering systemic delivery of targeted oncolytic virotherapy through the RedTail platform. NYSEAMERICAN: CLDI
- Industry
- Biotechnology Research
- Location
- San Diego, US
- Company size
- 11–50 employees
About Calidi Biotherapeutics
Calidi Biotherapeutics is developing a new modality in cancer treatment through its proprietary RedTail platform, designed for systemic delivery of modified oncolytic viruses with genetic payloads activated at the tumor site. Focused on patients with limited treatment options, the company is advancing therapies aimed at improving targeting, activity, and durability in solid tumors. Calidi continues to generate data and present at leading scientific meetings as it progresses toward early clinical data.
See moreLatest activity
Latest activity from Calidi Biotherapeutics
4 signals
Presence & Recognition
Calidi Biotherapeutics participated in the H.C. Wainwright & Co., LLC 28th Annual Global Investment Conference.
Research & Knowledge
Calidi Biotherapeutics CEO Eric Poma, Ph.D., shared his perspective on targeted immune activation, drug delivery, and tumor microenvironment therapeutic activity in a new article published in Morgan Kohler's Drug Discovery Online.
Presence & Recognition
Calidi Biotherapeutics CEO Eric Poma, Ph.D., shared insights into the future of systemically delivered oncolytic virotherapy in a recent Xtalks feature.
Discover more
Similar signals
Similar public activity from other companies.
Products & Services
Lytix Biopharma
Lytix Biopharma is developing first-in-class oncolytic molecules designed to kill tumors locally and activate broader systemic anti-tumor immunity.
Products & Services
Mestag Therapeutics
Mestag Therapeutics is advancing a novel approach to cancer therapy with MST-0312, an FAP-targeted LTβR agonist bispecific antibody designed to induce tertiary lymphoid structures and high endothelial venules in solid tumors.
Products & Services
Siren Biotechnology
Siren Biotechnology is advancing Universal AAV GeneTherapy for Cancer through its Childhood Cancer Awareness Month.
Research & Knowledge
Candel Therapeutics
Candel Therapeutics reported phase 3 data showing meaningful improvements in disease-free survival for aglatimagene besadenovec, an investigational viral immunotherapy designed to work alongside standard radiotherapy.
Research & Knowledge
BriaCell Therapeutics Corp.